Tom Homan, President-elect Donald Trump’s “border czar,” has a post that does not need Senate approval and could have less oversight by Congress, experts say.
Related Posts
Buy this biotech stock that can rally more than 65%, Goldman says
The firm opened coverage of the stock at a buy.
From mining giants to Big Oil, major players are jumping on the ‘white hydrogen’ bandwagon
Investor interest in the nascent sector has been intensifying, fueling optimism initially driven by research startups and junior exploration companies.
RFK Jr. tells Jim Cramer: Weight-loss drugs shouldn’t replace healthy eating, he’s not against all vaccines
“The first line of response should be lifestyle,” Robert F. Kennedy Jr. says.